Category Archives: Testosterone Replacement Therapy

Global Testosterone Replacement Therapy Market Research Report 2017 to 2022 provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure of the Testosterone Replacement Therapy Market.

Companies Mentioned are AbbVie, Pfizer, Eli Lilly, Teva Pharmaceuticals, Mylan, Bayer HealthCare Pharmaceuticals, Antares Pharma, Ferring Pharmaceuticals, Allergan, Antares Pharma, Sandoz, Clarus Therapeutics, Juniper Pharmaceuticals, Endo International, Acerus Pharmaceuticals, Forendo Pharma, MetP Pharma, Repros Therapeutics

The Global Testosterone Replacement Therapy market consists of different international, regional, and local vendors. The market competition is foreseen to grow higher with the rise in technological innovation and M&A activities in the future. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

This report segments the Global Testosterone Replacement Therapy market on the basis of types, Gels, Injectables, Patches, Other On the basis of application, the Global Testosterone Replacement Therapy market is segmented into Hospitals, Clinics, Other

Browse full report at: https://www.marketinsightsreports.com/reports/090117112/global-testosterone-replacement-therapy-market-professional-survey-report-2017

This independent 112 page report guarantees you will remain better informed than your competition. With over 165 tables and figures examining the Testosterone Replacement Therapy market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Testosterone Replacement Therapy in these regions, from 2012 to 2022 (forecast), covering Global, Europe, Japan, China, India , Southeast Asia, Other.

The report provides a basic overview of the Testosterone Replacement Therapy industry including definitions, classifications, applications and industry chain structure. And development policies and plans are discussed as well as manufacturing processes and cost structures.

Then, the report focuses on Global major leading industry players with information such as company profiles, product picture and specifications, sales, market share and contact information. Whats more, the Testosterone Replacement Therapy industry development trends and marketing channels are analyzed.

The research includes historic data from 2012 to 2016 and forecasts until 2022 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs. The report will make detailed analysis mainly on above questions and in-depth research on the development environment, market size, development trend, operation situation and future development trend of Testosterone Replacement Therapy on the basis of stating current situation of the industry in 2017 so as to make comprehensive organization and judgment on the competition situation and development trend of Testosterone Replacement Therapy Market and assist manufacturers and investment organization to better grasp the development course of Testosterone Replacement Therapy Market.

Inquire for sample copy at: https://www.marketinsightsreports.com/reports/090117112/global-testosterone-replacement-therapy-market-professional-survey-report-2017/inquiry

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

There are 15 Chapters to deeply display the Global Testosterone Replacement Therapy market.

Chapter 1, to describe Testosterone Replacement Therapy Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Testosterone Replacement Therapy, with sales, revenue, and price of Testosterone Replacement Therapy, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016and 2017;

Chapter 4, to show the Global market by regions, with sales, revenue and market share of Testosterone Replacement Therapy, for each region, from 2012to 2017;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;

Chapter 12, Testosterone Replacement Therapy market forecast, by regions, type and application, with sales and revenue, from 2017to 2022;

Chapter 13, 14 and 15, to describe Testosterone Replacement Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:-

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

+1 (704) 266-3234 | sales@marketinsightsreports.com

Connect With us on:

https://www.linkedin.com/company/13411016/

https://www.facebook.com/marketinsightsreports/

Tweets by MIRresearch

Visit link:
Testosterone Replacement Therapy Market Global Insights and ... - E News Access (press release)

As one of those whose passions were aroused by testosterone replacement therapy (TRT) in men, I am delighted that Clinical Pharmacist has provided Geoff Hackett with a platform to clarify the current clinical position (Clinical Pharmacist 2017;9:195). Hackett rightly points out that we should have no truck with those who have preconceived views on testosterone and interpret studies based on these preconceptions.

Indeed, with the feel of his erudite hand firmly on my collar, I confess that my own comments on this matter which used the inflammatory term male menopause (The Pharmaceutical Journal 2017;298;100) did not have the benefit of more recent studies quoted in this excellent article and I apologise if I appeared trite, cynical or indifferent. It is good to have a dispassionate, objective review of this subject focused on the facts.

My initial concerns about safety and efficacy of TRT were based on a letter from my colleague Sid Dajani (The Pharmaceutical Journal 2016;297:364) who appeared to me to be promoting the medicalisation of the ageing male population a population I am now part of and hope to be for some time by screening for low testosterone levels and, where identified, treating. In fact, I believe they should first stop smoking, reduce their drinking, take more exercise and relax. These steps would reduce their risk of cardiovascular disease and diabetes yet, I admit, they may not enjoy an early morning erection. Dajani was defiant about my concerns (The Pharmaceutical Journal 2017;298:235) over efficacy and I now know that I was wrong. There is good evidence for efficacy across a number of clear clinical outcomes. Hackett has convinced me of this.

But what about safety? Hackett attempts to convince me (and it may be just my stupidity so forgive me) but he seems to find studies that disagree with his case methodologically flawed whereas supportive studies do not attract such censure. I know that by saying that I risk being called out as one of the biased evangelical healthcare professionals dispensing their own standards of social justice. I hope not.

For example, he severely criticises the methodology in a paper published by Vigen et al[1]. The conclusion of this paper states: Long-term exposure to testosterone replacement therapy was associated with reduced risks of mortality, cardiovascular events, and prostate cancer. However, testosterone replacement therapy increased the risk of mortality and cardiovascular events with short durations of therapy. In view of the limitations of observational data and the potential for selection bias, these results warrant confirmation in a randomised trial.

I seem to understand what these authors are saying as; if the treatment does not kill you in the first few months then it might save your life. Very Nietzsche indeed.

I bow to Hacketts expertise on methodology. However, he also quotes a paper by Wallis et al[2] and without any criticisms of its methodology, quotes this study as supporting a decreased risk in all-cause mortality from TRT making no reference to the authors safety concerns: Use of testosterone therapy in this cohort of veterans with significant medical comorbidities was associated with increased risk of mortality, myocardial infarction, or ischaemic stroke. These findings were not modified by the presence of coronary artery disease. Future studies including randomised controlled trials are needed to properly characterise the potential risks of testosterone therapy in men with comorbidities.

This is clearly a complex clinical area. I would respectfully suggest that, accepting that TRT has an important clinical role when in the hands of experts such as Hackett, wider use of TRT is not a risk free-panacea for the ills of the ageing baby boomers.

Terry Maguire

Belfast

Citation: Clinical Pharmacist, CP August 2017 online, online | DOI: 10.1211/CP.2017.20203367

Originally posted here:
Wider use of testosterone therapy is not risk free - The Pharmaceutical Journal

Heres what Antonio Silvas career looks like over the past two years: Win (TKO), loss (TKO), loss (KO), loss (KO), loss (decision), loss (KO).

Hes been stopped by strikes in seven of his past 10 bouts. He has just two victories since 2012 one over Soa Palelei, and one over Alistair Overeem, who was beating him soundly until a sudden third-round comeback by Silva.

If you do some combat sports math on the 37-year-old Bigfoot, what you see is a fighter on a dangerous trajectory. That path took him out of the UFC and into two fights for smaller Russian promotions, both of which he lost. His last knockout loss was two months ago.

So why did Silva (19-12-1 MMA)just sign on for a kickboxing bout against GLORY heavyweight champion Rico Verhoeven (51-10-1 kickboxing)in China this October?

Obviously, its not a good fight for Bigfoot, Silvas longtime manager Alex Davis told MMAjunkie. Jumping right into (GLORY) to go against the current champ, whos a murderer? Yeah, we get it.

But Silvas doing it anyway, and for reasons that are as old as the fight game.

For one, he thinks he can win. According to Davis, Bigfoot is back on testosterone-replacement therapy, which he used somewhat controversially for a time in the UFC, before the practice was effectively banned.

Now, fighting in places like Russia and China, and for organizations whose anti-doping policies are notably less stringent, hes free to resume the use of synthetic testosterone, which makes a huge difference for him, Davis said.

And also he needs money, Davis said. He cant turn down fights at the moment for that reason. If it was up to me, he would not take this fight. But at the end of the day, my job is to inform him, give him my advice, and the one who has to make the final decision is him.

Here we get into a persistent problem for fighters and fight sports. No one can tell Silva to stop. They can suggest and argue and recommend. Promoters can cut him and trainers could refuse to train him. Even Davis, a longtime friend, could stop managing him.

But as long as Silva can find someone willing to pay for his name and his willingness to walk face-first into someone elses fists, he gets to keep going.

It was the same with Gary Goodridge, another MMA fighter who turned to kickboxing later in his career. He lost about twice as many kickboxing bouts as he won, but his appeal for promoters was that, when you booked Big Daddy, you knew someone would get knocked out even if the someone was usually him.

For Goodridge, those years of damage contributed to brain trauma that eventually left him unable to remember conversations moments after theyd ended. By the evening, he couldnt tell you what hed done during the afternoon.

But Goodridge also needed the money. Even when he knew he shouldnt fight anymore, he was a man in his forties with no real work history outside of cages and rings. What else was he supposed to do?

According to Davis, Silvas brain health has been closely monitored with testing done at the Cleveland Clinics Lou Ruvo Center for Brain Health in Las Vegas.

Physically, Bigfoot has no problems whatsoever, Davis said. He has no brain damage. Weve done extensive research and testing, even before he left the UFC. So hes OK on that end.

But then, some signs of degenerative brain diseases like CTE (chronic traumatic encephalopathy), which researchers have found in the brains of deceased fighters and football players, are sometimes not apparent until years after the actual trauma.

And clearly, Silva is doing himself no favors. He went less than five months between knockout losses in 2016. Youd have to go back to 2010 to find a single calendar year in which he didnt suffer at least one knockout.

This fight against Verhoeven doesnt promise to be any easier on his brain. Verhoeven is younger, faster, and riding a winning streak thats about as good as Silvas losing streak is bad. If anything, the kickboxing rules will likely only lead to Silva absorbing more punishment than he would in an MMA bout. And then what?

Soon the paycheck will be spent and Silva will face the same questions about his future that he faces now. So far, he only seems to know one answer.

Ill be very sincere and tell you, I cant defend a man from himself, Davis said. If he fights and doesnt manage his money, hell go looking for the next fight. This is a very common problem with many fighters, not just Bigfoot. Thats what creates situations like Gary Goodridge.

As for Goodridge, he also had people telling him he should stop. Then he had people telling him that there was something troubling happening to him. The damage sneaks up on you, he said later. When he finally realized the full extent of it, it was too late to stop it.

I had no idea it was coming, Goodridge said in 2012. You dont know. Everyone around you tells you its happening, but you dont notice it yourself.

For more on the upcoming MMA schedule, check out the MMA Rumors section of the site.

See original here:
Antonio Silva is on a troubling career trajectory, and there's no one who can stop him - MMAjunkie.com

Mooresville, NC (August 17, 2017) - 'Low T Center' is continuing their partnership with Reed Sorenson and Premium Motorsports as the team heads to Bristol Motor Speedway for this weekend's battle under the lights in the Monster Energy NASCARS Cup Series, 'Bass Pro Shops NRA Night Race'. Sorenson will be back in his familiar No.15 Chevrolet SS.

'Low T Center' is the leader of physician-led diagnosis and treatment of low testosterone with 50 locations nationwide and growing. Studies indicate testosterone deficiency has been linked to diabetes, metabolic syndrome, obesity, and high blood pressure. 'Low T Center' was designed so men can walk in, take a simple blood test, and know within 45 minutes if they are a candidate for Testosterone Replacement Therapy. Experience shows testosterone injections may lead to improved energy, strength, and libido, as well as decreases in body fat, irritability and depression. Most health insurance is accepted for treatment. Now with new locations in downtown Chicago,IL and Murfreesboro,TN.

To find your closest center and to learn more, go to https://lowtcenter.com.

--- Premium Motorsports ---

View post:
Low T Center returning to sponsor Sorenson - ESPN

Glory heavyweight champion Rico Verhoeven will return to the ring in a non-title bout on Oct. 14 in Gangzhou, China, taking on former UFC fighter Antonio Silva, but fans didnt seem to approve the match-up.

Bigfoot" was knocked out seven times over the past four years, winning only one of his last 10 MMA bouts, and never competed in a kickboxing fight before. Verhoeven, on the other hand, holds a 51-10-1 kickboxing record with wins over the likes of Badr Hari, Peter Aerts, Gokhan Saki and Sergei Kharitonov.

"Critics will always exist and we have to know how to deal with them, Silva told MMA Fighting. "Sometimes they dont even mean to criticize you, but they are just jealous they wanted to be a professional fighter and dont have that talent. I was always a humble person, I came from a humble family in Paraba and competed around the world, and some people dont accept that.

"Its a heavyweight fight and anything can happen. I respect Rico, he's the champion, but when I step into the ring anything can happen."

The criticism is not of Silva taking a fight against the champion, but toward the promotion for booking someone who has been knocked out many times recently against the best heavyweight kickboxer on the planet.

Asked if someone in his team was against the match-up for health reasons, Silva said it was quite the opposite.

"As soon as we received the offer, everyone was in favor of it, "Bigfoot" said. "My manager, Alex Davis, said it was a good fight because he knows me and knows I can go there and put on a good fight. Everyone supported me because the impossible doesnt exist. If you go in there thinking that you cant do it, that hes the No. 1, or if you go there for the money, you already lost. I dont think like that. Im not going there for money or media, Im going there because I know I can put on a good fight."

"I went five rounds with Mark Hunt, and we stood and fought for 22 minutes. I knocked out (Alistair) Overeem, a K-1 champion, he continued. "Every athlete has to be versatile. I started in karate, but I always trained everything. Not having to worry about getting taken down or being pressed against the cage makes the camp and the actual fight easier."

Silva started his camp three weeks ago, as soon as he was offered the fight, and is excited about the challenge.

"Its a new experience for me, he said. "Im a professional athlete for years and I like to try new things, new challenges. I feel like an amateur going for his first fight, trying to show what he can do, and God willing everything will be alright.

The Brazilian heavyweight started in martial arts in karate, training for 12 years until he turned 17 and decided to add jiu-jitsu to his game. Now, he says, I train muay thai and boxing four times a week."

For his kickboxing debut, Bigfoot" will move his camp to his hometown Brasilia, Brazil, to train with UFC veteran Guto Inocente, a second-degree kickboxing black belt who holds a 34-8 kickboxing record, 5-1 under the Glory banner. Silva also invited Pedro Rizzo to join his camp in Brasilia.

"Rico is the champion, he deserves a lot of respect, Silva said. "Hes the best heavyweight kickboxer in the world. Im an amateur, its my first kickboxing fight, and I want to show what I can do. I have nothing to prove, I have no responsibility. Rico has the responsibility, hes the champion. The pressure is on him. Im cool."

The 37-year-old heavyweight compares his Glory debut to Conor McGregors upcoming clash with boxing legend Floyd Mayweather, when the UFC lightweight champion steps into the boxing ring for the first time against a 49-0 professional boxer in Las Vegas.

"Its a similar situation, Silva said. "McGregor never boxed and is going there to try to surprise. He has no pressure over himself because 99 percent of the people bet on Mayweather. Hes undefeated, 49-0, so most of the people think he will win. Its the same thing in this fight. But were two human beings stepping into a ring to fight. Anything can happen in a heavyweight fight, one hand can land and change the story."

"Im rooting for McGregor, he added. "He deserves respect. Hes a two-division champion in the UFC and is making history. Him as a person, he talks a lot, I dont consider him an idol, but he deserves respect. Anything can happen in this fight. Im rooting for him even though I think Mayweather will win because hes 49-0 and always trained that, so its complicated. But everything is possible."

According to Silva, hes getting paid "much more" in his recent fights compared to his previous bouts in the UFC, but thats not the only difference in this fight. The Brazilian heavyweight, who was only allowed to use testosterone replacement therapy once in the UFC against Mark Hunt, when he ended up testing positive for elevate testosterone levels restarted the treatment before his last MMA fight.

"My case is not for muscular gain or to enhance performance, but for health issues, said Silva, who lost his last fight to former Bellator heavyweight champion Vitaly Minakov in Russia. "I really need this in my life to be physically and mentally well. Ive fought in the UFC when my testosterone levels were at 77 three weeks before the fight. That's the level of a 90-year-old man. My levels were always low, 300, when someone at my age would be 800. I have doctors following me, making sure my levels are always at the normal range.

Continued here:
'Bigfoot' Silva responds to criticism of Rico Verhoeven fight, compares it to Mayweather vs. McGregor - MMA Fighting

We hate to say it, but low testosterone levels can have a slew of negative effects for older guys.

But even now there's a scientific tug-of-war over testosterone-replacement therapy. Sure, it sounds greatwhat guy doesn't want more of the "masculine hormone"?but risks of testosterone therapy can include the growth of pre-existing cancerous cells, testicular shrinkage, infertility, even heart attack or stroke, as one of our writers discovered.

The positives are just as extreme. Aside from increased strength and motivation, men can enjoy greater urinary health, better sexual function, and a higher quality of life, according to new research from Boston University Medical Center.

In the study, published in the Journal of Urology, researchersenrolled roughly 650 men in their 50s and 60s. Some of the men had unexplained testosterone deficiencies, while others suffered from genetic hypogonadism (when gonads fail to produce testosterone). About 360 men received testosterone therapy for eight years (the remaining didn't).

What's more, the men who underwent testosterone therapy enjoyed a significant bump in their urinary and sexual function (lower instance of erectile dysfunction, higher sex drive), as well as better quality of life (sunnier mood, higher confidence).

Another interesting detail: Two men in the treatment group died from causes unrelated to cardiovascular failure, while 21 in the non-treatment group died (19 deaths were cardiovascular-related). Those mortality rates suggested that testosterone therapy isn't necessarily linked to a greater instance of heart attack or stroke, the researchers suggested.

"It is thought that testosterone treatment in men may increase prostate size and worsen lower urinary tract symptoms," study author Abdulmaged Traish, Ph.D., said in a press release. Researchers discovered somemenhad larger prostates post-testosterone therapy, but they experienced fewer instances of frequent urination, incomplete bladder emptying, and waking at night to urinate.

"[Testosterone therapy] is well-tolerated with progressive and sustained improvement in urinary and sexual function, and overall improvement in quality of life," Traish added.

Something to think about if your testosterone takes a hit one day and you want to fight manopause head-on.

Excerpt from:
Older men with 'low T' can improve their sex lives with testosterone therapy, study says - Men's Fitness

New York Long-term testosterone replacement therapy improves both sexual and urinary functions as well as quality of life for men suffering from a condition due to deficiency of the hormone, according to a study.

Testosterone is a steroid hormone involved in the regulation of sexual function, urinary health and metabolism as well as a number of other critical functions.

For most men, testosterone concentration declines slowly with age and may not cause immediate major symptoms.

However, some men may experience a host of signs and symptoms constituting a clinical condition called Testosterone Deficiency (TD), or male hypogonadism, which is attributed to insufficient levels of testosterone.

Office Portrait of MED Prof. Dr. Abdulmaged TraishPhoto by Vernon Doucette for Boston University Photography

As a result, they experience symptoms as varied as erectile dysfunction, low energy, fatigue, depressed mood and an increased risk of diabetes.

The study, published in the Journal of Urology, investigated the effects of long-term testosterone replacement therapy on urinary health and sexual function as well as quality of life in men with diagnosed, symptomatic testosterone deficiency.

More than 650 men in their 50s and 60s enrolled in the study, some with unexplained testosterone deficiency and others with known genetic and auto-immune causes for their hypogonadism.

It is thought that testosterone treatment in men may increase prostate size and worsen lower urinary tract symptoms, said Abdulmaged Traish, Professor of Urology at Boston University School of Medicine in the US.

However, the researchers discovered that despite increased prostate size in the group that received testosterone therapy, there were fewer urinary symptoms such as frequent urination, incomplete bladder emptying, weak urinary stream and waking up at night to urinate.

In addition to these subjective improvements, the researchers conducted objective testing that showed that those men treated with testosterone emptied their bladders more fully.

Finally, testosterone treatment also increased the scores patients received on assessments of their erectile/sexual health and general quality of life, the study said.

Related

Read the original post:
Testosterone therapy improves sexual functions - India New England

Report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products.

This press release was orginally distributed by SBWire

Albany, NY -- (SBWIRE) -- 08/16/2017 -- The topic of Hypogonadism can be an embarrassing subject for an affected male. Nevertheless, it's important that any man battling the symptoms of Hypogonadism to get over his embarrassment and be taken care of by a medical professional. A new pipeline study, related to the therapeutics activities for male hypogonadism has been recently broadcasted to the wide repository of Market Research Hub (MRH), with the title of "Male Hypogonadism-Pipeline Insight, 2017". The study highlights the pharmacological action of various therapeutics and their history of research and development activities.

Request Free Sample Report : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265411

Male hypogonadism is defined as the failure of the testes to produce androgen, sperm or both. Although the disorder is extremely common, its exact prevalence is uncertain. It is a condition in which the body doesn't produce enough testosterone, the hormone that plays a key role in masculine growth and development during puberty. It may adversely affect multiple organ functions and quality of life. Signs and symptoms depend on when the condition develops. The research analyses its symptoms, which include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). When hormone levels decline, men can easily experience significant psychological and physical changes.

Moreover, this study provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The coverage of pipeline products based on the numerous stages of development ranging from early development to approved or issued stage. In this subsequent section, details of foremost pipeline products which includes, product description, licensing and collaboration details and other developmental activities are also mentioned. This study has been built using proprietary databases along with latest updates and featured news & press releases from various university sites and industry-specific third party sources.

Looking to the therapeutics overview, the research studies that the levels of testosterone in men start to fall after the age of 40. It has been estimated that 8.4% of men aged 5079 years have testosterone deficiency. Some types of male hypogonadism can be treated with testosterone replacement therapy. There is a lot of research in progress to find out more about the effects of testosterone in older men and also whether the use of testosterone replacement therapy would have any benefits.

Browse Full Report with TOC - http://www.marketresearchhub.com/report/male-hypogonadism-pipeline-insight-2017-report.html

For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends and their efforts to discover new therapeutics for male hypogonadism. Also, the report covers dormant and discontinued pipeline projects related to the Male Hypogonadism. With this information, the new entrants in the market can modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress.

Enquire about this Report - http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1265411

About Market Research HubMarket Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us90 State Street,Albany, NY 12207,United StatesToll Free : 866-997-4948 (US-Canada)Tel : +1-518-621-2074Email : press@marketresearchhub.comWebsite : http://www.marketresearchhub.com/Read Industry News at - https://www.industrynewsanalysis.com/

For more information on this press release visit: http://www.sbwire.com/press-releases/pipeline-landscape-of-male-hypogonadism-covering-therapeutic-assessment-and-drug-portfolio-in-2017-848559.htm

Here is the original post:
Pipeline Landscape of Male Hypogonadism Covering Therapeutic Assessment and Drug Portfolio in 2017 - Digital Journal

Testosterone is a major sex hormone produced in the testes of men. The pituitary gland is responsible for controlling the production of testosterone hormone. In the testes, luteinizing hormone binds to receptors on Leydig cells; this stimulates production and secretion of testosterone. Testosterone helps to develop the primary and secondary sexual characteristics in males. Development of sex organs, deeper voice, muscle mass, and facial hair all result from the sufficient production of this hormone. Testosterone deficiency as happens with age needs effective testosterone treatment.

Along with the development of sexual features, testosterone hormone also controls the following actions in a body:

With age, testosterone production declines, thus disturbing overall body functioning. Low levels of testosterone hormone lead to a condition termed as hypogonadism that can be treated with testosterone replacement therapy. Hypogonadism can be divided into two categories depending on the occurrence of pathology.

Primary Hypogonadism: It occurs at testicular level with high release of follicle stimulating hormone (FSH), luteinizing hormone (LH), and low release of testosterone.

Secondary Hypogonadism: It occurs at pituitary hypothalamic level with low or in some cases normal release of luteinizing hormone and follicle stimulating hormone along with low levels of testosterone hormone.

Testosterone replacement therapy effectively works to improve upon the conditions of primary and secondary hypogonadism.

Along with aging, there are some other factors that contribute toward low testosterone production and make a man go for testosterone treatment.

Deficient testosterone hormone levels can lead to many undesirable symptoms, like poor libido, lack of vitality, erectile dysfunction, declining muscle mass, osteoporosis, loss of body hair, depression, lower blood hemoglobin, memory loss, poor concentration, mood swings, mild anemia, disturbed cholesterol profile and a decrease in cognitive function that effects all of your activities. Testosterone therapy is the only possible way to cope with testosterone deficiency.

Before start of the testosterone treatment, there should be the right detection of the hormone deficiency. If you consult an expert doctor for testosterone therapy, he may prescribe you the blood test in the morning because testosterone levels are at peak during that time.

We, at Nationwide Synergy Inc, provide patients with best available options to treat their hormone deficiency.

Choosing one best option for testosterone therapy requires consultation with your physician. We have qualified physicians and doctors at our panel who provide expert guidance to the patients.

Stay Young and Healthy with Balanced Hormones Testosterone Replacement Therapy Is Your best Choice!

Follow this link:
Testosterone Replacement Therapy - Testosterone Treatment

Weve had a seemingly endless series of discussions about the various aspects of the transgender debate here, many of which focus on the continued and worrisome spread of normalization gender dysphoria in society, the military and beyond. But one of the side-bar aspects of this discussion has had to do with the world of sports. Whether youre talking about a girl wrestling against boys or comparing the Bobby Riggs vs Billy Jean King tennis match to Renee Richards, questions of gender bending in the competitive arena come with all sorts of complications.

Now another sport is being featured in this ongoing debate and its the world of competitive cycling. For the first time a man identifying as a woman will be racing in a USA Cycling sanctioned event in the womens category and competing against some of the top female cyclists. Jillian Bearden (formerly Jonathan) is going to be competing in the Colorado Classic and is able to do so because both the International Olympic Committee and Cycling USA have removed the requirement for transgender athletes to have their transition surgery prior to being able to compete. What theyve done instead is require that men transitioning to be women spend at least one year on medication to suppress their testosterone production, increase estrogen and keep their T levels below a certain, unspecified level. (It will come as no surprise that there are no parallel testing requirements for women identifying as men.) From theDenver Post:

The new rules simply require transwomen to keep testosterone below a certain level for a year before competing and must present a doctors note showing their testosterone levels are below the IOC threshold. The IOC recommendations include no restrictions for athletes transitioning to male.

USA Cycling was one of the first national governing bodies to embrace the new policy, thanks in part to Beardens help. She had the science to support the new rules.

As an elite male racer, she had regular benchmarks measuring her power and lactate threshold. After more than two years of blocking testosterone and boosting estrogen, her wattage output has dropped by 11.4 percent. That mirrors the performance gap between top-tier male and female athletes.

Bearden has done precisely that and claims that his performance has decreased substantially from his days cycling as a man. Because of that, the argument goes, theres no problem with him having any sort of unfair advantage.

Bearden has watched her performance ebb since beginning hormone-replacement therapy in 2015. As testosterone fades and estrogen grows, her fastest times on favorite climbs have slipped into what she calls the gutter.

It was tough realizing her hard-earned power, developed over more than a decade of elite-level bike racing, was waning.

I went from 16 minutes to 26, 27, 28 minutes, she said of her times on her those climbs. I was like holy Testosterone gives you this drive, this oomph, and I didnt have that push.

Ill confess I hadnt given much thought to this aspect of it. The difference in performance levels between men and woman in all of these sports is well known, and letting a guy compete with the women would be grossly unfair. But if you suppress his testosterone levels enough, will his performance really degrade far enough to keep things competitive?

Hed better have suppressed it a lot. I was looking over some of the current records for cycling in the 24 hour competitions on both road and track. (Thats the distance you can ride in 24 hours.) The womens road record currently stands at just under 470 miles. The mens record? 557 miles. The indoor and outdoor track records similarly have a disparity of one hundred miles or more in the mens favor. Is a vastly decreased T level enough to make that much of a difference? While its not being applied to gender dysphoria situations, several medical resources indicate that markedly lower levels have an impact, but precisely how much is unknown and can vary from individual to individual.

Because testosterone plays a role in building muscle, men with low T might notice a decrease in muscle mass. Studies have shown testosterone affects muscle mass, but not necessarily strength or function.

The major problem here is that we dont have a baseline to study. Because of a lack of professional or Olympic records (at least as far as I can find and they arent mentioned in the Denver Post article) we have no idea how great of a cyclist Jonathan Bearden was before he started riding as Jillian Bearden. If he winds up coming in at the back or in the middle of the pack Im sure everyone will be all smiles and say it was great having him in the race. But what has that really proved? The best woman cyclist in the world will no doubt be able to smoke a mediocre male rider while the top flight men would leave her in the dust based on current Olympic records. Were looking at a situation similar in some ways to the aforementioned tennis scenario with Renee Richards. Keep in mind that he was in his mid to late 30s already by the time he was entering tennis full time and was certainly competent, but was only ranked in the top 20 in the over 35 category. Yet when playing as a woman Richards reached a ranking of 20th overall (against the best female players of any age) in 1979 and reached the womens doubles finals at the US Open that year.

That leaves us with an open question as to how well hell do in this race and, perhaps more importantly, how well hell be received. Its been a rousing and supportive welcome thus far, but if Bearden waltzes in there and wins (or comes fairly close) having no real racing bona fides beforehand, do you suppose all of the female competitors are still going to be quite so supportive and welcoming?

Stay tuned. Well have some of those answers later this month.

Read the original post:
Yes, let's chat about that first female transgender pro cyclist shall we? - Hot Air